SCHEMBL716459

SCHEMBL716459

Cc1cc(C)cc(/C=C/c2ccc(O)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.64
PTGS1 P23219 4/20 0.64
ALOX5 P09917 4/20 0.64
PTGS2 P35354 4/20 0.64
KDM4E B2RXH2 3/20 0.64
MEN1 O00255 3/20 0.64
MAPT P10636 3/20 0.64
KMT2A Q03164 3/20 0.64
TTR P02766 3/20 0.64
CYP1A1 P04798 3/20 0.64
CYP1B1 Q16678 3/20 0.64
NQO2 P16083 3/20 0.64
CA12 O43570 2/20 0.64
CA1 P00915 2/20 0.64
CA2 P00918 2/20 0.64
CA3 P07451 2/20 0.64
CA4 P22748 2/20 0.64
CA6 P23280 2/20 0.64
CA5A P35218 2/20 0.64
CA7 P43166 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716460 1.00 APP (0.64) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL9605419 0.91 PTGS1 (0.72) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL17570320 0.91 PTGS1 (0.72) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL9571496 0.83 ACHE (0.68) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL14038080 0.83 ACHE (0.68) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL11932608 0.83 ACHE (0.68) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL12535853 0.83 PTGS2 (0.80) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL10281605 0.83 PTGS1 (0.62) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL13409624 0.83 APP (0.79) APPPTGS1ALOX5PTGS2KDM4E
SCHEMBL9605420 0.81 ALOX5 (0.65) APPPTGS1ALOX5PTGS2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118773236-B Technology for biologically converting resveratrol into pterostilbene by using yarrowia lipolytica 谷雨生物科技集团股份有限公司 2025-06-03 CN disclosed
CN-118773236-A Technology for biologically converting resveratrol into pterostilbene by using yarrowia lipolytica 广州梵之容化妆品有限公司 2024-10-15 CN disclosed
US-20200188878-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2020-06-18 US disclosed
US-20200188878-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2020-06-18 US disclosed
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-10-06 US disclosed
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-10-06 US disclosed
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-10-06 US disclosed
EP-2391658-B1 MOLECULARLY IMPRINTED POLYMERS COMMW SCIENT IND RES ORG (AU) 2015-09-23 EP disclosed
US-20120135091-A1 METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES US ARMY, SECRETARY OF THE ARMY 2012-05-31 US disclosed
US-20120135091-A1 METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES US ARMY, SECRETARY OF THE ARMY 2012-05-31 US disclosed
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2012-03-01 US disclosed
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2012-03-01 US disclosed
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2012-03-01 US disclosed
EP-2391658-A1 MOLECULARLY IMPRINTED POLYMERS Commonwealth Scientific and Industrial Research Organisation (AU) 2011-12-07 EP disclosed
WO-2010085851-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2010-08-05 WO disclosed
WO-2010085851-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2010-08-05 WO disclosed
US-20100168084-A1 Therapeutic compounds and related methods of use ELIXIR PHARMACEUTICALS, INC. 2010-07-01 US disclosed
US-20100168084-A1 Therapeutic compounds and related methods of use ELIXIR PHARMACEUTICALS, INC. 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS IPMK, MPI, PIM3 APP 3642/4885PTGS1 1822/4885ALOX5 1635/4885
US-20100168084-A1 Therapeutic compounds and related methods of use EP300, KAT2A, KAT6B APP 3630/4885PTGS1 3012/4885ALOX5 1466/4885
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS IPMK, MPI, PIM3 APP 3642/4885PTGS1 1822/4885ALOX5 1635/4885
US-20120135091-A1 METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES HSF1, SIRT1, SIRT2 APP 1811/4885PTGS1 168/4885ALOX5 1792/4885
US-20200188878-A1 MOLECULARLY IMPRINTED POLYMERS IPMK, MPI, PIM3 APP 3642/4885PTGS1 1822/4885ALOX5 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.